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The asplenic patient is at risk of overwhelming post-splenectomy infection (OPSI) due to encapsulated
bacteria, namely pneumococcus, haemophilus inﬂuenza B and meningococcal C pathogens. The lifetime
risk is 1–2%with the estimatedmortality being in the region of 40–70% (Davidson RN,Wall RA. Prevention
and management of infections in patients without a spleen. Clin Microbiol Infect 2001;7:657–60).
Preventative measures include appropriate prophylactic vaccination, long term antibiotics and patient
education. Guidelines for the prevention and treatment of infection in patients with an absent or
dysfunctional spleen were ﬁrst published by the British Committee for Standards in Haematology in
1996, with a revised edition published in 2002. There are a number of permutations of these guidelines
published by a number of professional bodies and consequently this has led to variable adherence rates
to such guidelines. We review the perioperative administration of prophylactic vaccinations.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Pneumococcal immunisation
Pneumococcal immunisation with polyvalent capsular poly-
saccharide vaccine is uniformly recommended for asplenic and
hyposplenic patients.2–4 The currently available polyvalent pneu-
mococcal vaccine (PPV23) contains capsular polysaccharides from
23 serotypes, responsible for upto 90% of the serotypes that cause
invasive pneumococcal infections.5
The vaccine should be administered a minimum of 2 weeks
prior to elective splenectomy to ensure an optimal antibody
response.6,7
Studies have demonstrated the immunogenicity of the 23
valent pneumococcal vaccine is best when given on day 14 post-
operatively, with functional immunoglobulin G antibody levels
approaching those of control subjects with intact spleens.7
However, the same authors found there is no difference in serum
antibody concentrations in comparison to normal controls when
the vaccine is given immediately, or 14 days post-operatively;
consequently it has been advocated by the British Committee forciates Ltd. Published by Elsevier LtStandards in Haematology that the pneumococcal vaccine must be
administered in the immediate post-operative period.2
In children under the age of 2, the developing immune system is
too immature to mount an appropriate antibody response to
polysaccharide antigens. If splenectomy is unavoidable in this age
group, a conjugate 7 valent pneumococcal vaccine provides a more
reliable serological response.2,8 In splenectomised children over the
age of 2, the polyvalent pneumococcal vaccine has been reported to
be safe and immunogenic.9
Reimmunisation of asplenic patients is currently recommended
every 5 years.10 This is due to the decline in serum antibody level in
the ﬁrst few years after initial vaccination. Giebink et al observed
a linear decline in serum antibody concentration from 32% to 24%
from the peak antibody level within the ﬁrst 12 months post-
vaccination.11 Decisions on reimmunisation may be made on the
basis of antibody levels.
2. Haemophilus inﬂuenza type B immunisation
The role of haemophilus inﬂuenza in OPSI is unclear; however
the protein conjugate vaccine is thought to be immunogenic in
asplenic patients, and is therefore recommended.12 It should be
administered to all asplenic patients who have not been previouslyd. All rights reserved.
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least 2 weeks post-operatively in emergency cases.13
3. Meningococcal immunisation
Immunisation with the meningococcal C conjugate vaccine is
part of the routine childhood immunisation programme in the UK
at 3 months, 4 months and 12months of age. The conjugate vaccine
is immunogenic, providing long term immunological memory, and
it is therefore recommended in all patients at least 2 weeks prior to
elective splenectomy or at least 2 weeks post-emergency
splenectomy.12
Other forms of available meningococcal vaccinations include
a bivalent polysaccharide vaccine against serogroups A and C and
a quadrivalent vaccine against serogroups A, C, Y andW135.1 Travel
to areas where other serogroups of meningococci are prevalent is
an indication for revaccination with the bivalent or quadrivalent
vaccine.
4. Inﬂuenza immunisation
Annual inﬂuenza immunisation is recommended in all asplenic
patients as it reduces the risk of secondary pneumococcal and
haemophilus inﬂuenza infections.5
5. Contraindications
Contraindications to immunisation include a concurrent acute
febrile illness, systemic steroid therapy or immunosuppressive
therapy. In such cases vaccinations should be administered on
resolution of the situation. It is recommended that immunisation
be delayed for at least 3 months after immunosuppressive
chemotherapy or radiotherapy to ensure an optimal immune
response, during which time prophylactic antibiotics should be
administered.2
6. Antibiotic prophylaxis
The value of long term antibiotic prophylaxis in the splenec-
tomised adult has not been effectively assessed in a clinical trial.14Life-long antibiotic prophylaxis may be a risk factor for the selec-
tion of resistant strains. The efﬁcacy of long term antibiotics may be
reduced due to non-compliance.15 Consequently, long term anti-
biotic prophylaxis in adults is generally not recommended.2
In splenectomised children antibiotic prophylaxis is recom-
mended up till the age of 16, with the recommended antibiotic
being amoxicillin in children.1 For patients with a penicillin allergy
alternatives include co-trimoxazole or a ﬂuoroquinolone such as
moxiﬂoxacin.14
All asplenic patients should be provided with a 5 day course of
stand-by antibiotics, to be commenced if symptoms or signs of
infection develop with advice to seek immediate medical attention.
The recommended antibiotic for adults is co-amoxiclav 625 mg
8-hourly or cefuroxime 250 mg 12-hourly in those with a penicillin
allergy.147. Guidelines
Based on published data and current guidelines, our recom-
mendations are depicted in Fig. 1.8. Conclusion
The consequences of OPSI are overwhelming and can be
minimised by appropriate immunoprophylaxis. We have under-
taken a review of the current guidelines and have attempted to
produce a clear, concise guide to immunoprophylaxis in the
asplenic patient.Conﬂict of interest
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